Evidence map›Paper›PMID 39767212›Full record

ArticleDiagnostics (Basel, Switzerland)2024

Comparison of Vendor-Pretrained and Custom-Trained Deep Learning Segmentation Models for Head-and-Neck, Breast, and Prostate Cancers.

Xinru Chen, Yao Zhao, Hana Baroudi, Mohammad D El Basha, Aji Daniel, Skylar S Gay, Cenji Yu, He Wang, Jack Phan, Seungtaek L Choi and 9 more

Abstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Xinru ChenDepartment of Radiation Physics, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-9989-8943
Yao ZhaoDepartment of Radiation Physics, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-8863-841X
Hana BaroudiDepartment of Radiation Physics, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-9921-4663
Mohammad D El BashaDepartment of Radiation Physics, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Aji DanielDepartment of Radiation Physics, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Skylar S GayDepartment of Radiation Physics, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0003-4659-0766
Cenji YuDepartment of Radiation Physics, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
He WangDepartment of Radiation Physics, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-4904-531X
Jack PhanDepartment of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-5977-6004
Seungtaek L ChoiDepartment of GU Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Chelain R GoodmanDepartment of Breast Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Xiaodong ZhangDepartment of Radiation Physics, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Joshua S NiedzielskiDepartment of Radiation Physics, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Sanjay S SheteThe University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston, TX 77030, USA.ORCID 0000-0001-7622-376X
Laurence E CourtDepartment of Radiation Physics, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-3241-6145
Zhongxing LiaoDepartment of Thoracic Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-2224-9478
Fredrik LöfmanRaySearch Laboratories AB, 113 68 Stockholm, Sweden.
Peter A BalterDepartment of Radiation Physics, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jinzhong YangThe University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston, TX 77030, USA.ORCID 0000-0002-9254-4501

Funding

Paul Calabresi Clinical Oncology AwardK12CA088084 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI David S. Hong, Scott Kopetz · 2000 to 2026
$14.0M
Project 3: Inhibiting Oxidative Phosphorylation in Pancreatic CancerP50CA221707 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KOPETZ, SCOTT · 2019 to 2023
$11.0M
Risk prediction and longitudinal assessment of cardiotoxicity and functional capacity trajectory in NSCLC patientsR01HL157273 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LIAO, ZHONGXING · 2021 to 2025
$3.8M
NCI NIH HHS K12 CA088084NCI NIH HHS P50 CA221707NHLBI NIH HHS R01 HL157273NIH HHS P30016672NIH HHS R01HL157273-01Radiation Oncology Institute ROI2022-9133The University of Texas MD Anderson Cancer Center start-up funds
6 · The paper itself

Abstract

BACKGROUND/

objectivesWe assessed the influence of local patients and clinical characteristics on the performance of commercial deep learning (DL) segmentation models for head-and-neck (HN), breast, and prostate cancers.

methodsClinical computed tomography (CT) scans and clinically approved contours of 210 patients (53 HN, 49 left breast, 55 right breast, and 53 prostate cancer) were used to train and validate segmentation models integrated within a vendor-supplied DL training toolkit and to assess the performance of both vendor-pretrained and custom-trained models. Four custom models (HN, left breast, right breast, and prostate) were trained and validated with 30 (training)/5 (validation) HN, 34/5 left breast, 39/5 right breast, and 30/5 prostate patients to auto-segment a total of 24 organs at risk (OARs). Subsequently, both vendor-pretrained and custom-trained models were tested on the remaining patients from each group. Auto-segmented contours were evaluated by comparing them with clinically approved contours via the Dice similarity coefficient (DSC) and mean surface distance (MSD). The performance of the left and right breast models was assessed jointly according to ipsilateral/contralateral locations.

resultsThe average DSCs for all structures in vendor-pretrained and custom-trained models were as follows: 0.81 ± 0.12 and 0.86 ± 0.11 in HN; 0.67 ± 0.16 and 0.80 ± 0.11 in the breast; and 0.87 ± 0.09 and 0.92 ± 0.06 in the prostate. The corresponding average MSDs were 0.81 ± 0.76 mm and 0.76 ± 0.56 mm (HN), 4.85 ± 2.44 mm and 2.42 ± 1.49 mm (breast), and 2.17 ± 1.39 mm and 1.21 ± 1.00 mm (prostate). Notably, custom-trained models showed significant improvements over vendor-pretrained models for 14 of 24 OARs, reflecting the influence of data/contouring variations in segmentation performance.

conclusionsThese findings underscore the substantial impact of institutional preferences and clinical practices on the implementation of vendor-pretrained models. We also found that a relatively small amount of institutional data was sufficient to train customized segmentation models with sufficient accuracy.

Indexed as

auto-segmentationcommercial segmentationradiotherapyU-Net

Identifiers

PMID39767212
PMCPMC11675285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.